Immuron shares surge 23.56% premarket after U.S. DoD awards therapeutic development and clinical trial updates.

Immuron surged 23.56% in premarket trading following the announcement of a U.S. Department of Defense-funded collaboration to develop two novel oral therapeutics targeting Campylobacter and Shigella, alongside an update on its clinical trial for Travelan®. The company highlighted a new research agreement with military research institutes, leveraging its proprietary hyper-immune bovine colostrum technology to create pre-clinical candidates for the U.S. military. Additionally, the Uniformed Services University’s P2TD clinical trial evaluating Travelan® for travelers’ diarrhea is expected to release topline results soon. These developments underscore progress in Immuron’s pipeline for diarrheal disease prevention, addressing critical unmet needs in military and traveler populations, and validate its platform technology. The news aligns with the stock’s sharp premarket rise, reflecting investor optimism about the company’s strategic partnerships and clinical milestones.